IL318380A - Treatment for acute organ injury using cd39, recombinant cd39 - Google Patents

Treatment for acute organ injury using cd39, recombinant cd39

Info

Publication number
IL318380A
IL318380A IL318380A IL31838025A IL318380A IL 318380 A IL318380 A IL 318380A IL 318380 A IL318380 A IL 318380A IL 31838025 A IL31838025 A IL 31838025A IL 318380 A IL318380 A IL 318380A
Authority
IL
Israel
Prior art keywords
recombinant
treatment
organ injury
acute organ
acute
Prior art date
Application number
IL318380A
Other languages
Hebrew (he)
Inventor
Claudio Calonder
Ghionul Ibram
Guido Junge
Matthew James Rowland
Max Philipp Taubert
Max Warncke
Hermann Markus Weiss
Yinong Zhou
Original Assignee
Novartis Ag
Claudio Calonder
Ghionul Ibram
Guido Junge
Matthew James Rowland
Max Philipp Taubert
Max Warncke
Hermann Markus Weiss
Yinong Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Claudio Calonder, Ghionul Ibram, Guido Junge, Matthew James Rowland, Max Philipp Taubert, Max Warncke, Hermann Markus Weiss, Yinong Zhou filed Critical Novartis Ag
Publication of IL318380A publication Critical patent/IL318380A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL318380A 2022-07-29 2023-07-27 Treatment for acute organ injury using cd39, recombinant cd39 IL318380A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263369839P 2022-07-29 2022-07-29
PCT/IB2023/057612 WO2024023745A1 (en) 2022-07-29 2023-07-27 Treatment for acute organ injury using cd39, recombinant cd39

Publications (1)

Publication Number Publication Date
IL318380A true IL318380A (en) 2025-03-01

Family

ID=87570979

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318380A IL318380A (en) 2022-07-29 2023-07-27 Treatment for acute organ injury using cd39, recombinant cd39

Country Status (8)

Country Link
EP (1) EP4561608A1 (en)
JP (1) JP2025524942A (en)
KR (1) KR20250044705A (en)
CN (1) CN119604301A (en)
CA (1) CA3262869A1 (en)
IL (1) IL318380A (en)
TW (1) TWI891029B (en)
WO (1) WO2024023745A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025184468A1 (en) * 2024-02-28 2025-09-04 University Of Massachusetts Measurement of urine thromboxane metabolites to predict survival

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38299A (en) * 2018-07-18 2020-02-28 Novartis Ag SOLUBILIZED APIRASES, METHODS AND USES

Also Published As

Publication number Publication date
CN119604301A (en) 2025-03-11
WO2024023745A1 (en) 2024-02-01
KR20250044705A (en) 2025-04-01
EP4561608A1 (en) 2025-06-04
TW202404627A (en) 2024-02-01
JP2025524942A (en) 2025-08-01
CA3262869A1 (en) 2024-02-01
TWI891029B (en) 2025-07-21

Similar Documents

Publication Publication Date Title
IL308698A (en) Tissue treatment system
IL315403A (en) Mirdametinib treatment
CA226061S (en) Pet dental treat
CA227912S (en) Dental treat
CA3262869A1 (en) Treatment for acute organ injury using cd39, recombinant cd39
GB202405551D0 (en) Combination treatment
CA223597S (en) Hydrotherapy apparatus, medical apparatus
GB202319954D0 (en) Treatment
GB202319658D0 (en) Treatment
GB202319443D0 (en) Treatment
GB202318845D0 (en) Treatment
GB202311007D0 (en) Treatment
GB202304853D0 (en) Treatment
GB202218460D0 (en) Treatment
GB202214206D0 (en) Treatment
GB202212125D0 (en) Treatment
GB202204288D0 (en) Treatment
GB202204070D0 (en) Treatment
GB202212566D0 (en) Combination treatment
GB202201069D0 (en) Treatment
GB202307730D0 (en) Wood treatment
CA218194S (en) Pet dental treat
IL318179A (en) Tissue processing
GB202313014D0 (en) Novel therapeutic treatment
GB202300613D0 (en) Tobacco treatment